<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01747057</url>
  </required_header>
  <id_info>
    <org_study_id>MORESS</org_study_id>
    <nct_id>NCT01747057</nct_id>
  </id_info>
  <brief_title>Monitoring Resuscitation in Severe Sepsis and Septic Shock</brief_title>
  <official_title>Monitoring Resuscitation in Severe Sepsis and Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corporacion Parc Tauli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corporacion Parc Tauli</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our hypothesis is that hemodynamic fluid resuscitation guided by dynamic parameters will
      improve outcome in patients with severe sepsis and septic shock, by limiting the deleterious
      effects of fluid overload.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the efficacy of dynamic parameters versus static measures to guide fluid
      resuscitation we pretend to detect a 10% relative reduction in mortality. In addition, we
      pretend to observe an improvement on the length of resuscitation time, mechanical ventilation
      and vasopressor support-free days, ICU and hospital length of stay, organ failure and renal
      function.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality at 28 days</measure>
    <time_frame>28 days after hospital admission</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of resuscitation</measure>
    <time_frame>72 hours after protocol inclusion</time_frame>
    <description>Vasopressor use and fluid load between 0h to 6h
Vasopressor use and fluid load between 7h to 72h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free days</measure>
    <time_frame>28 days after admission</time_frame>
    <description>From 1 to 28 days over 28 days in a month.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasopressor-free days</measure>
    <time_frame>28 days after admission</time_frame>
    <description>From 1 to 28 days over 28 days in a month.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ failure-free days</measure>
    <time_frame>28 days after admission</time_frame>
    <description>Cardiovascular, CNS, renal, hepatic, coagulation abnormalities. From 1 to 28 days over 28 days in a month.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>At ICU discharge (expected average 30 days after admission)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>At hospital discharge (expected average 45 days after hospital admission)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function evolution</measure>
    <time_frame>3 days after study enrollment</time_frame>
    <description>Creatinin clearance will be calculated every day for the first 3 days (Cockroft-Gault formula).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality at 3 months</measure>
    <time_frame>3 months after admission</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">952</enrollment>
  <condition>Hemodynamics</condition>
  <arm_group>
    <arm_group_label>Dynamic guide resuscitation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm follows a resuscitation protocol based on dynamic-parameters-guided fluid management.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard resuscitation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm follows a common resuscitation protocol based on Surviving Sepsis Campaign recommendations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Dynamic-parameters-guided fluid management</intervention_name>
    <description>● In preload-responsive patients defined by the following dynamic parameters: Patients fully adapted to mechanical ventilation* and with sinus rhythm.
PPV &gt;12%. PPV: Pulse pressure variation PPV = (PPmax-PPmin)/ [(PPmax+PPmin)/2] x100 (during 5 respiratory cycles)
SVV &gt; 12% (15). SVV: Stroke volume variation
A tidal volume (Vt) ≥ 7-10cc/kg in mechanically ventilated (in a controlled mode - control volume or control pressure) and well-adapted patients without any inspiratory effort should be guaranteed.
Fluid loading must be performed with crystalloids (1omL/Kg) or colloids (5ml/Kg) every 30 minutes until PPV-SVV &lt; 12%, while hypoperfusion signs are present. Continue resuscitation following Surviving Sepsis Campaign rules excluding more fluid administration (as described in the standard intervention once CVP&gt;12).
● Non-preload responsive patients (defined as PPV or SVV &lt; 12%) will resume the same protocol as responders when fluid response parameters are negative.</description>
    <arm_group_label>Dynamic guide resuscitation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standard-guided-fluid management</intervention_name>
    <description>Fluid loading in patients with hypotension or elevated lactates until normalization of MAP (&gt; 65mmHg) or CVP &gt; 12mmHg. If CVP reaches &gt; 12 mmHg and MAP remains &lt; 65mmHg, norepinephrine should be started to reach MAP &gt; 65mmHg. Once MAP is restored, if hypoperfusion signs persist (elevated lactate or urine output &lt; 0.5mL/Kg/h), ScvO2/SvO2 must be measured. In order to reach a ScvO2 ≥70% or SVO2 ≥65%, consider giving blood transfusion if hemoglobin level (Hb) ≤ 7g/dL, and also consider dobutamine (initial dose 2,5 µg/kg/min, increased by 2,5 µg/kg/min every 30 min up to a maximum dose of 20 µg/kg/min, presence of arrhythmia, or FC&gt;110bpm). At that point, if hypoperfusion signs remain present, consider restart protocol from the beginning.</description>
    <arm_group_label>Standard resuscitation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Clinical evidence of sepsis (microbiology confirmation, radiological or direct view -
             pus in biological fluid or surgical direct view-).

          -  ≥ 2 SIRS criteria:

               -  Temperature &lt; 36.0°C or &gt; 38.0°C

               -  Heart rate &gt; 90 bpm

               -  Respiratory rate &gt; 20 rpm or PaCO2 &lt; 32 mmHg or need of mechanical ventilation.

               -  Leukocytes &gt; 12.0 x109/L or &lt; 4.0 x109/L

          -  Hemodynamic insufficiency defined as (at least one of the following):

               -  Sustained systemic hypotension (systolic arterial pressure ≤ 90 mmHg or MAP &lt; 65
                  mmHg) or a decrease in MAP of &gt; 30 mm Hg in a hypertensive patient.

               -  Need of vasopressors.

               -  Tachycardia (HR &gt; 110 bpm) or bradycardia (HR &lt; 55 bpm)

               -  Acute onset of oliguria, defined as a decreased urine output &lt; 0.5 ml/kg/hr for ≥
                  2 hours

               -  Serum lactate &gt; 2 mmol/l

               -  Peripheral cyanosis, mottled skin, prolonged capillary refill

          -  Mechanical ventilation without any kind of inspiratory effort and Vt 7-10 mL/Kg,
             Pplateau &lt; 30 mmH2O. Those patients with ARDS under mechanical ventilation will need
             to tolerate a tidal volume of at least 7 mL/Kg during 30 seconds while the plateau
             pressure remains &lt; 30 mmH2O.

          -  Prior hemodynamic monitoring by arterial catheter.

          -  Central venous catheter.

        Exclusion Criteria:

          -  Acute myocardial infarction &lt; 7 days.

          -  Pregnancy

          -  Prior request of limited code status or expected life length lower than 3 months.

          -  Shock &gt; 12h

          -  Cardiac arrhythmia

          -  Aortic valvular disease

          -  Inability to properly measure arterial pressure wave forms
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xaime Garcia, MD</last_name>
    <phone>+34937231010</phone>
    <phone_ext>21156</phone_ext>
    <email>xgarcia@tauli.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gisela Gili, RN</last_name>
    <phone>+34937231010</phone>
    <phone_ext>21159</phone_ext>
    <email>ggilis@tauli.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Area de Critics. Hospital de Sabadell</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gemma Goma, RN</last_name>
      <phone>937231010</phone>
      <phone_ext>21179</phone_ext>
      <email>ggoma@tauli.cat</email>
    </contact>
    <investigator>
      <last_name>Xaime Garcia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillem Gruartmoner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.edusepsis.org/proyectos_fic.php?id_pro=10</url>
    <description>Spanish webpage of the study</description>
  </link>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2012</study_first_submitted>
  <study_first_submitted_qc>December 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2012</study_first_posted>
  <last_update_submitted>February 12, 2014</last_update_submitted>
  <last_update_submitted_qc>February 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Corporacion Parc Tauli</investigator_affiliation>
    <investigator_full_name>Antonio Artigas Raventós</investigator_full_name>
    <investigator_title>Director of Critical Care Area</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

